Silexion Therapeutics price to book ratio SLXN
Market value divided by the book value of the company's net assets, since 2025.
- Today, Nov 2, 2026
- 18.7×
- Peer median
- 0.5×
Silexion Therapeutics' price to book ratio is 18.7× as of Nov 2, 2026.
The median for 10 biotech stocks of a similar size is 0.5×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 18.7× | 0.3× | 55.0× |
| 2025 | 1.0× | 1.0× | 44.6× |
Against its peers
Companies in Biotechnology nearest Silexion Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| SLXNSilexion Therapeutics | 18.7× |
| CRISCuris | 0.3× |
| CLDICalidi Biotherapeutics | 0.5× |
| VIVSVivoSim Labs, INC. | n/m |
| PMCBPharmaCyte Biotech | 0.1× |
| LIMNLiminatus Pharma | 11.3× |
| CELZCreative Medical Technology | 0.5× |
| AIMAIM ImmunoTech | 0.6× |
| SNTISenti Biosciences | n/m |
| INABIN8BIO | 0.5× |
| PASGPassage BIO | 2.4× |
| Peer median | 0.5× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Silexion Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.